Levostar
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Levostar - overview
Established
2022
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Suzhou, China, and established in 2022, Suzhou Zuoxuanxing Biotechnology Co. , Ltd. doing business named Levostar, is a biotechnology company that focuses on providing cell and gene therapy clinical products testing and production. Its team members are from Cornell University, Tsinghua University, Peking University, and other universities and corporations.
It completed the seed fund in August 2022, then raised pre-series A funding in January 2023. Besides, it started to build the lab in May 2022 and then performed testing services in October 2022. In June 2023, the firm raised pre-series A funding from new investor Hengxu Capital. The company self-developed multiple testing and analysis platforms, including strain banking & testing, cell library development and testing, plasmid quality control platform, viral vector QC platform, mRNA QC platform, and CAR cell QC platform.
It also operates as a contract Design & Manufacture Organization (CDMO), and provides different levels of plasmids and mRNA.
Current Investors
Bohe Angel Fund, Jifeng Ventures, MPC
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare, Pharmaceutical Research & Development
Website
www.levostar.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.